• Studies on the effect of sibutramine, an anti-obesity drug, on hormonal and metabolic features of women with polycystic ovary syndrome (PCOS) are lacking. (
  • To the authors' best knowledge, the effect of sibutramine, a serotonin and noradrenaline reuptake inhibitor (SNRI) approved as antiobesity drug, has been studied in only one study with obese women with PCOS. (
  • In Northern Ireland, during 2009/2010 orlistat accounted for approximately 80% of prescriptions for anti-obesity medication increasing to 99% following the withdrawal of sibutramine. (


  • There are only a few studies on the effect of anti-obesity drug administration in obese and overweight women with PCOS. (


  • Any number of factors could affect the dosage needs for an anti-epileptic medication, however, various lines of evidence suggest that characteristics of the patient's epilepsy itself could be important determinants. (
  • One option is the use of anti-obesity medication the prescription of which has increased dramatically in recent years. (
  • Despite this, little is known about the individual and GP practice factors that influence the prescription of anti-obesity medication. (
  • Multi-level logistic regression analysis was used to investigate factors associated with the prescription of anti-obesity medication in Northern Ireland using a population primary care prescribing database (~1.5 million people aged 16+ years) during 2009/10. (
  • While 25.0% of people are obese, only 1.3% (2.1% of females, 0.6% of males) received anti-obesity medication. (
  • Prescribing of anti-obesity medication reflected obesity prevalence across urban/rural areas and deprivation. (
  • There was an unexplained two-fold difference, between the 25th and 75th percentile, in the GP practice prescription of anti-obesity medication. (
  • While the prevalence (and presumably the health consequences) of obesity worsens with age, younger females are more likely to be prescribed anti-obesity medication. (
  • Educational material to improve the understanding of the role of anti-obesity medication, for patients and practitioners, is recommended. (
  • Orlistat (brand names Xenical/Alli) was first introduced in the UK and Europe in 1998 and is currently the main treatment option for those prescribed anti-obesity medication. (
  • Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. (


  • Topiramate is an anti- epileptic drug that is approved for the treatment of epilepsy in adults and children 2 years of age and above. (
  • Topiramate is an anti-epileptic drug that is approved for epilepsy either alone (i.e., monotherapy), or in combination with other anti-epileptic medications, in adults and children 2 years of age and above. (


  • In recent years, pharmacological treatment for obesity has been increasing against a backdrop of decreasing choice of available anti-obesity medications. (


  • Most primary care settings do not provide much obesity treatment, though, as primary care providers (PCPs) are not well trained and because reimbursement for treatments is not consistent. (
  • The remainder of the registry's patients can still receive obesity treatment but will not be reimbursed. (
  • Impact: If the study is successful, we plan to take the results to the leaders at Denver Health to see if they will make obesity treatment more broadly available for all patients there. (
  • The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity. (


  • Patients who have been identified by their physicians as candidates for initial anti-epileptic monotherapy will be enrolled. (


  • Although lean women present PCOS, obesity is one of the main manifestations of the syndrome. (


  • Oleuropein and hydroxytyrosol exhibit anti-diabetic and antioxidant actions. (


  • A range of treatments have shown to be effective for treating obesity. (


  • Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof. (


  • There is evidence of relative under-prescribing in males compared to females despite a similar prevalence of obesity. (


  • Several studies have demonstrated that obesity in women with PCOS enhances the clinical and metabolic abnormalities of the syndrome, since obese women with PCOS have more profound insulin resistance or type 2 DM,dyslipidemia and cardiovascular disease's risk, and greater level of androgens due to low SHBG levels. (


  • Powdered Gymnema sylvestre, Citrulus colocynthis, and Artemisia absinthium possess good anti-diabetic features. (


  • Oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits. (